FDA Approves NovoSeven庐 RT for Glanzmann鈥檚 Thrombasthenia

July 8, 2014

On July 7, 2014, the US Food and Drug Administration (FDA) approved NovoSeven庐 RT, a recombinant factor VIIa product manufactured by NovoNordisk, as the first recombinant treatment for Glanzmann鈥檚 Thrombasthenia (GT). The approved indication is for bleeding episodes and perioperative management for patients in whom platelet transfusions, with or without antibodies to platelets, is ineffective. […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.